Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.

Ming CuiSami ShoucairQuan LiaoXiaoyan QiuBenedict Kinny-KösterJoseph R HabibElie M GhabiJunke WangEun Ji ShinSean X LengSyed Z AliElizabeth D ThompsonJacquelyn W Zimmerman Christopher R Shubert Kelly J LafaroRichard A BurkhartWilliam R BurnsLei ZhengJin HeYupei ZhaoChristopher L WolfgangXin Yu

Published in: International journal of surgery (London, England) (2023)

Assessment of SIA-IgG on FNA specimens prior to NAT may help predict PR for PDAC. Additionally, SIA-IgG expression in treatment-naïve FNA specimens and surgically resected primary tumor specimens were predictive of the prognosis for PDAC.

Keyphrases

fine needle aspiration
ultrasound guided
lymph node
poor prognosis
papillary thyroid
rectal cancer
locally advanced
squamous cell
binding protein
long non coding rna
prognostic factors
mesenchymal stem cells
cell therapy